Sir,
We acknowledge the discussion points raised by Schöffski et al (2010), both in their letter and in their prospective evaluation of sunitinib-induced hypothyroidism published in this journal in 2008 (Wolter et al, 2008).
We reported on a small, open-label, phase II clinical trial of sunitinib on a continuous daily dosing schedule in patients with advanced NSCLC and, as noted in the discussion section of the paper, the primary end point of this trial (the reporting of at least five objective responses) was not reached. However, despite the low overall response rate, we were encouraged by the time-to-event results obtained, which we feel are concordant with a signal of activity and with time-to-event data observed on Schedule 4/2 (4 weeks on treatment followed by 2 weeks off; Socinski et al, 2008). Furthermore, as this was not a phase III trial designed to definitively assess the activity of sunitinib in patients with lung cancer, we feel justified in reporting intriguing observations pertaining to antitumour activity. Conclusive efficacy statements cannot, and have not, been made in this paper and we believe that the interpretation of the trial data was suitably guarded.
Schöffski et al also suggest correlations between the effect of sunitinib on thyroid function and the incidence of fatigue in our trial. There were few data to support such a correlation at the time our trial was designed; consequently, thyroid function measurement was not part of the clinical protocol. Nevertheless, we acknowledge that 53–85% of oncology patients treated with sunitinib develop thyroid test abnormalities, and a substantial percentage develop clinical manifestations of thyroid dysfunction (Desai et al, 2006; Rini et al, 2007). Guidance for the use of sunitinib in its licensed indications is available and recommends baseline laboratory measurement of thyroid function, with hyper- and hypothyroidism treated as per standard medical practice. Studies investigating the impact of sunitinib therapy on thyroid function are ongoing.
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK (2006) Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145: 660–664
Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM (2007) Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Can Inst 99: 81–83
Schöffski P, Garfield DH, Hercbergs A, Wolter P . Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors. Br J Cancer 2010 102: 1309–1310
Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC, Scagliotti GV (2008) Multicenter, phase II trial of sunitinib in previously treated, advanced non-small cell lung cancer. J Clin Oncol 26: 650–656
Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schöffski P (2008) The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 99: 448–454
Acknowledgements
Editorial/medical writing support was provided by Nicola Crofts PhD at ACUMED (Tytherington, UK) and was funded by Pfizer Inc.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Novello, S., Scagliotti, G., Rosell, R. et al. Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors. Br J Cancer 102, 1311 (2010). https://doi.org/10.1038/sj.bjc.6605629
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6605629